Department of Psychiatry

Speaker Bios – Depression Guidelines 2016 & Psychopharmacology Update Conference

Click here for a list of workshop descriptions.

abbey

Dr. Susan Abbey’s research and clinical interests have been related to the psychiatric care of patients in the medical and surgical setting, somatization and somatic symptom disorders and the use of mindfulness-based stress reduction (MBSR) in the management of medical illness.

Dr. Abbey serves as the Psychiatrist-in-Chief for the University Health Network Centre for Mental Health. She has held leadership positions in the Canadian Psychiatric Association, the Canadian Academy of Psychosomatic Medicine and the American Psychiatric Association.


bowieDr. Christopher Bowie is a Professor in the Departments of Psychology and Psychiatry, and a member of the Centre for Neuroscience Studies, at Queen’s University in Kingston, Ontario. He is the Head Consulting Psychologist for the Head’s Up Early Psychosis Intervention Program in Kingston and a Clinician Scientist at the Centre for Addiction and Mental Health in Toronto. His research interests focus on determining the causes and correlates, and developing treatments for, cognitive deficits in chronic mental disorders such as schizophrenia and mood disorders. He completed his Ph.D. at Hofstra University and was awarded the Association for Psychological Science’s award for Top Ranked Thesis in the country. After his doctoral internship at the Clinical Neuroscience Center of Pilgrim Psychiatric Center, he did post-doctoral training with Dr. Barbara Cornblatt where he supervised neuropsychological testing and studied cognitive treatment outcomes in adolescents at risk for psychosis, earning a Young Investigator Award from the National Alliance for Research in Schizophrenia and Depression (NARSAD). Dr. Bowie then took an academic appointment at Mount Sinai School of Medicine and continued to study the functional consequences of cognitive impairment in schizophrenia before moving to Queen’s in 2008. He has been awarded two additional NARSAD Awards to study cognitive remediation in schizophrenia and in 2011 received the Top-Ranked Young Investigator Fellow at the annual Winter Brain Conference. He is the author of over 100 peer reviewed scientific publications and several books and book chapters on cognition in chronic mental illness, including a co-editor of: Cognitive Remediation to Improve Functional Outcomes. Currently he is leading multiple trials of cognitive remediation for chronic mental disorders and studying early intervention for mental illness.


giacobbeDr. Peter Giacobbe is a staff psychiatrist at the University Health Network (UHN) in Toronto, where he serves as the Head of the Electroconvulsive Therapy Service, co-Head of the rTMS service and Director of the Fellowship Program. He is an Assistant Professor in the Department of Psychiatry at the University of Toronto, with appointments in the Division of Brain and Therapeutics and the Division of Geriatric Psychiatry. He completed medical school at the University of Western Ontario, followed by residency, Fellowship training and graduate school at the University of Toronto. Dr. Giacobbe’s clinical and research interests focus on the development and evaluation of novel pharmacological and neuromodulatory treatment strategies for individuals with treatment-resistant mood disorders. He co-authored the 2009 and 2016 CANMAT Neurostimulation Guidelines for the Treatment of Depression.  Dr. Giacobbe has published over 45 papers on the topics of mood disorders and brain stimulation in journals including the the American Journal of Psychiatry, Biological Psychiatry, Brain Stimulation, Canadian Journal of Psychiatry,  CMAJ, Experimental Neurology, The Journal of Neurosurgery, Lancet, Neuropsychopharmacology and Psychiatric Services.


gratzerDr. David Gratzer is a Toronto-based psychiatrist and physician. He works at The Scarborough Hospital, where he is physician-in-charge of Mental Health inpatient services, and is the physician co-lead for consultation-liaison services. He is active in teaching, and has received the specialist teacher of the year award twice, and nominated six times for University of Toronto teaching awards. He is a member of the national editorial board of CAMH’s Portico and serves on the OMA’s Section on Psychiatry Executive. He recently joined the editorial board of The Canadian Journal of Psychiatry.


goldsteinDr. Benjamin Goldstein is a child and adolescent psychiatrist and Associate Professor of Psychiatry, Pharmacology, and Psychological Clinical Science at the University of Toronto.  He is Director of the Centre for Youth Bipolar Disorder and Director of Research in the Department of Psychiatry at Sunnybrook Health Sciences Centre. Dr. Goldstein’s efforts focus on teenagers with, or at familial risk for, bipolar disorder. His team seeks to identify clinically relevant biomarkers, and innovative prevention and treatment strategies that focus simultaneously on physical and mental health. Dr. Goldstein has authored over 100 scientific articles, and has received international awards for his research. His research is funded by grants from CIHR, the Ontario Ministry of Research & Innovation, and by foundations in Canada and the United States. An active educator, Dr. Goldstein serves as Director of the Clinician Scientist Program in the University of Toronto’s Department of Psychiatry.


kennedyjDr. James L. Kennedy is Head of Molecular Science and Head of the Tanenbaum Centre for Pharmacogenetics in CAMH’s Campbell Family Mental Health Research Institute. He is the I’Anson Professor in the Department of Psychiatry and Institute of Medical Science at the University of Toronto. Dr. Kennedy’s research is dedicated to finding genes involved in the cause of mental illness. He has published pioneering findings relating gene variants in the dopamine, serotonin, and neurodevelopment systems to psychiatric disorders, and to treatment response. Dr. Kennedy has also led investigations using powerful DNA sequencing technology to understand genetic variation and function in great detail. Currently he is applying molecular genetic technology to the study of schizophrenia, obsessive compulsive disorders, bipolar disorder, anxiety disorders, eating disorders, addictions, personality disorders and attention deficit hyperactivity disorder. In addition, Dr. Kennedy is investigating genetic factors that may predict response and side effects to psychiatric medications (pharmacogenetics). Another important area of interest is the integration of molecular genetics and neuroimaging (MRI, PET) as a combination approach to better understand brain structure and function.


kennedyDr. Sidney H. Kennedy is Professor of Psychiatry at the University of Toronto, a Scientist at Li Ka Shing Knowledge Institute and the Krembil Research Institute, Toronto, Canada. He also holds an appointment at St. Michael’s Hospital as the Arthur Sommer-Rotenberg Chair in Suicide Studies and Depression. Dr. Kennedy is the lead investigator for a multi-centre depression biomarker initiative collectively known as the Canadian Biomarker Integration Network for Depression(CAN-BIND). He has published extensively on new drug evaluation, neuroimaging and neurostimulation therapies, personality factors in depression, antidepressant effects on sexual function and led initiatives to develop treatment guidelines for Major Depressive Disorder and Bipolar Disorder. He is the Immediate Past President of the International Society for Affective Disorders and a former President of the Canadian College of Neuropsychopharmacology, the founding chair of the Canadian Network for Mood and Anxiety Treatments (CANMAT). In 2016 Dr. Kennedy became an elected Fellow of the Canadian Academy of Health Sciences He has published more than 350 peer reviewed publications and 11 books on depression and related topics.


lamRaymond W. Lam is Professor and BC Leading Edge Chair in Depression, and Associate Head for Research, in the Department of Psychiatry, University of British Columbia, and Director of the Mood Disorders Centre of Excellence at the Djavad Mowafaghian Centre for Brain Health in Vancouver. His research covers the spectrum of non-pharmacologic and pharmacologic treatments for mood disorders, with a focus on e-mental health, seasonal, treatment-resistant and workplace depression. He has published almost 300 papers in peer-reviewed journals and authored 11 books on depression, and serves on the editorial boards of 10 international journals, including as an editorial advisor for the Cochrane Collaboration. He is also a lead investigator for the Canadian Biomarker Integration Network in Depression (CAN-BIND, www.canbind.ca) and the Executive Chair of the Canadian Network for Mood and Anxiety Treatments (CANMAT, www.canmat.org).


sunderjiDr. Glenda MacQueen earned her PhD in Psychology and her medical degree from McMaster University, where she also completed her residency in psychiatry.  In 2008 she moved from McMaster to the University of Calgary where she is currently Vice Dean in the Cumming School of Medicine and a member of the Hotchkiss Brain Institute and the Mathison Centre for Mental Health Research and Education.  Her research interests have focused on mood disorders. Dr. MacQueen is an associate editor of the Canadian Journal of Psychiatry and the Journal of Psychiatry and Neuroscience. She currently sits on the Board of Directors of the Palix Foundation and the Calgary Drop In and Rehab Centre. She was the 2011 recipient of the Douglas Utting award for studies in depression and is the 2014 recipient of the Heinz Lehmann award from the Canadian College of Neuropsychopharmacology.


roumen-milevDr. Roumen Milev graduated medicine in Sofia, Bulgaria in 1983, obtained Specialty of Psychiatry in Bulgaria, MRCPsych in England and FRCPC in Canada. Defended his PhD in Forensic Psychiatry. In 1995 he moved to Regina, Canada where he became Medical Director of the Mental Health Clinic. In 2001 he was appointed Clinical Director of the Mood Disorder Research and Treatment Service in Kingston. In 2007 he became the Head of Department of Psychiatry at Queen’s University.

He is actively involved in research with patients with Depression, Bipolar Disorder, Anxiety Disorders, and other Affective Disorders. Main areas of his research include issues of Stigma and ways of dealing with it, Sleep architecture, psychopharmacological and rTMS treatments.

Dr. Milev has many publications and significant teaching experience.  He lead workshops and panel discussions at conferences and has presented numerous lectures to Psychiatrists, Family Physicians and other health professionals.   Dr. Milev is involved actively in both undergraduate and postgraduate teaching, including supervision of masters and PhD students. He has been involved with CANMAT guidelines for management of patients with Bipolar Disorders, and with Depression. He has won several prizes and awards.


mulsant2Dr. Benoit Mulsant is Professor and Chair of the Department of Psychiatry, University of Toronto and a Senior Scientist at the Centre for Addiction and Mental Health (CAMH) in Toronto. He has authored and co-authored more than 400 peer-reviewed journal articles and 50 book chapters and invited publications. Over the past 25 years, the over-arching goal of his research work has been to improve the treatment of older persons with severe mental disorders.  His scientific focus has been on designing and conducting clinical trials for “hard–to-treat” older patients with geriatric depression, treatment-resistant depression, psychotic depression, late–life bipolar disorder, schizophrenia, and dementia. Over the past decade, his collaborators and he have been involved in efforts to identify biomarkers associated with late-life mental disorders based on new advances in pharmacogenetics, neuroimaging, and neurophysiology.  He has a small clinical practice focused on older patients with mood disorders and cognitive disorders (dementia). He has been listed in Best Doctors in America and Best Doctors in Canada.


sagarDr. Sagar Parikh is adjunct Professor of Psychiatry at the University of Toronto, where he was on staff full-time from 1994-2015. In March 2015, Dr. Sagar Parikh was appointed as the John F. Greden Professor of Depression and Clinical Neuroscience, and Professor of Psychiatry, at the University of Michigan, Ann Arbor, where he was also designated Associate Director of the Michigan Comprehensive Depression Center. At the University of Toronto, he previously served as Head of General Psychiatry and Director of Continuing Mental Health Education. He also completed two terms as Deputy Psychiatrist-in-Chief at the University Health Network in Toronto and was previously head of the Bipolar Clinic and Director of Continuing Education at CAMH.

Dr. Parikh is the author / editor of two books and over 150 peer-reviewed articles and book chapters, and co-author of CANMAT treatment guidelines for Depression and for Bipolar Disorder, the world’s most cited mood disorder guidelines. He holds research grants from multiple funding agencies, covering studies in clinical treatments in mood disorders, health services research, genetics, epidemiology, and educational research. He has conducted clinical trials looking at the combination of medication and psychotherapy for bipolar disorder and for depression, as well as pharmacotherapy trials in mood disorders. Current major projects include a multi-site study of Biomarkers in Major Depression, Functional / Cognitive Remediation for Bipolar Disorder and Depression, Workplace Depression interventions, a RCT of Pharmacogenomic Testing to aid treatment of Depression, and a RCT of Telephone-Delivered CBT for Bariatric Surgery patients. As medical director of Mensante, he helped create a novel internet system for recognition and management of mental disorders that is commercially marketed.

Dr. Parikh serves as Secretary of the International Society for Affective Disorders, and Co-Head, Section of Affective Disorders, World Psychiatric Association; Medical Director, National Network of Depression Centers (USA); and Education Chair, CANMAT (Canadian Network for Mood and Anxiety Treatments).  He is the recipient of multiple awards for research, teaching, and service.


rajjiiDr. Tarek Rajji is Chief in Geriatric Psychiatry at the Centre for Addiction and Mental Health (CAMH) and Associate Professor of Psychiatry at the University of Toronto

Dr. Rajji obtained his M.D. from the American University of Beirut, Lebanon. He completed residency in general psychiatry at the University of Texas Southwestern Medical Center and clinical training in geriatric psychiatry at Western Psychiatric Institute and Clinic in Pittsburgh. In 2006, he joined CAMH and the University of Toronto as a research fellow in geriatric psychiatry and then as a clinician scientist and an Assistant Professor of Psychiatry in December 2009. He was promoted to Associate Professor in July 2013. Dr. Rajji is a Fellow of the Royal College of Physicians and Surgeons of Canada and certified by the American Board of Psychiatry and Neurology with subspecialty in Geriatric Psychiatry.

Dr. Rajji has been leading several clinical initiatives at CAMH. He also received numerous research awards and honors. His research is supported by private, provincial, federal, national, and international agencies.

Dr. Rajji’s research focuses on restoring brain function in older patients with severe mental illness and Alzheimer’s disease. Towards this goal, he combines brain stimulation, cognitive, functional, and pharmacological methods to study and enhance neuroplasticity across the lifespan with a special focus on late life.


remingtonGary Remington is a Senior Scientist in the Campbell Family Mental Health Research Institute and Chief of the Schizophrenia Division at CAMH. He is also Professor of Psychiatry at the University of Toronto. Dr. Remington’s research focus is the pharmacotherapy of schizophrenia, particularly as it applies to the pharmacology and clinical profile of antipsychotics and decision-making in treatment. The approach is translational and integrates preclinical and clinical lines of investigation. More recently, the focus has turned to distinguishing pathophysiological subtypes of schizophrenia based on clinical response.


richterDr. Peggy Richter is the inaugural head of the Frederick W. Thompson Anxiety Disorders Centre and Director of the Clinic for OCD & Related Disorders at Sunnybrook Health Sciences Centre.  She is an associate professor of psychiatry at the University of Toronto, and serves as an associate scientist in the Sunnybrook Research Institute and an affiliate scientist in the Neurogenetics Program at the Centre for Addiction and Mental Health.  Dr Richter is internationally known for her work in obsessive-compulsive disorder (OCD), focusing her research on exploration of the genetic and biological basis of this illness, as well as better defining the boundaries of OC-Related Disorders and improving treatment outcome.   Dr Richter is the author of numerous publications and scientific presentations, and is a member of the editorial board for the Journal of Obsessive-Compulsive and Related Disorders. She recently co-authored the book “Cognitive Behavioral Therapy for Anxiety” in the series “Psychotherapy Essentials to Go”.  She serves on the Steering Committee of the Toronto Hoarding Support Services Network, the board of directors of the Canadian OCD Network, and on the Scientific Advisory Board of the Canadian Institute for Obsessive Compulsive Disorder.  She is an internationally acclaimed speaker on anxiety, presenting extensively to both health care professionals and lay audiences.


andriyDr. Andriy V. Samokhvalov is a staff psychiatrist and clinician-scientist with CAMH Addictions Program and Institute for Mental Health Policy Research and assistant professor at the Department of Psychiatry of the University of Toronto. He has a number of publications in the field of addictions with the main focus on epidemiology of alcohol-related problems. In the past 3 years his main clinical and research focus was in clinical trials and clinical research in concurrent disorders as well as integrated treatment models and quality of care. Dr.Samokhvalov is the Co-Lead and the Principal Investigator of the DA VINCI Project which aims to provide evidence-based integrated treatment model for concurrent major depressive disorder and alcohol use disorder across the province of Ontario, Canada.


schafferAyal Schaffer is Head of the Mood and Anxiety Disorders Program, and Deputy Psychiatrist-in-Chief, at Sunnybrook Health Sciences Centre, Toronto, Canada.  He is an Associate Professor in the Department of Psychiatry, University of Toronto, Vice President Education for the International Society for Bipolar Disorders, and on the Board of the Canadian Network for Mood and Anxiety Treatments (CANMAT).

Dr. Schaffer’s research interests involve the management of bipolar disorder and treatment-resistant depression, understanding suicide risk and prevention, and examining population-health trends in the treatment of mental illness.  Dr. Schaffer has been a principal or co-investigator of studies funded by the Ontario Mental Health Foundation, Canadian Institute of Health Research, National Institute of Mental Health (U.S.), Ontario Ministry of Health and Long-Term Care, PSI Foundation, American Foundation for Suicide Prevention, the Stanley Medical Research Institute, and others, and has authored over 80 peer-reviewed articles and chapters.

Dr. Schaffer co-authored the CANMAT / ISBD Guidelines for the Management of Bipolar Disorder as well as co-leading the CANMAT Task Force on Comorbidity in Mood Disorders.  He recently chaired the International Society for Bipolar Disorders Task Force on Suicide.  Dr. Schaffer has an outpatient and inpatient practice at Sunnybrook, where he is also chair of the Department of Psychiatry Quality Improvement Committee.  He is actively involved in teaching at the undergraduate, postgraduate, and continuing educations levels.


sockalingamDr. Sanjeev Sockalingam is an Associate Professor of Psychiatry at the University of Toronto and Deputy Psychiatrist-in-Chief at the University Health Network for the Toronto General and Princess Margaret Hospital sites. He is the Director of the Bariatric Surgery Psychosocial Program.  He is also the co-lead for the Extension for Community Healthcare Outcomes (ECHO) Ontario Mental Health at the Centre for Addiction and Mental and Health and the University of Toronto, which is a provincial hub-and-spoke knowledge-sharing network model building mental health and addiction capacity in rural Ontario.

Dr. Sockalingam is the Director of Continuing Practice and Professional Development for the Department of Psychiatry at the University of Toronto. He is also the Director of Curriculum Renewal for the Medical Psychiatry Alliance and supervises a range of trainees including medical students, residents and fellows in medical psychiatry.

Dr. Sockalingam has >100 peer-reviewed publications and he is a lead investigator on several peer-reviewed grants. His clinical and research interests include understanding psychiatric morbidity in medical and surgical patients and improving service delivery to improve physical and mental health outcomes. He is also involved in research in medical education and knowledge translation.


sunderjiDr. Nadiya Sunderji is a psychiatrist and a researcher in quality improvement and education in the area of integrated / collaborative mental health care. She is the physician lead for quality improvement in the St. Michael’s Hospital Mental Health and Addictions Service and an Assistant Professor and Lead for integrated mental health care education in the Department of Psychiatry at the University of Toronto. She has a Master’s in Public Health from Johns Hopkins University, is a member of the Delta Omega Alpha Honour Society, and was recently awarded the Association for Academic Psychiatry’s Early Career Development Award.

Dr. Sunderji’s research aims to improve the implementation of collaborative mental health care models in primary care settings. Collaborative care models have been widely adopted, yet implementation is highly variable, frequently does not conform to evidence based practice, and has rarely been evaluated. Furthermore, evaluation frameworks and metrics are lacking. In her funded research, Dr. Sunderji is developing a quality framework and quality measures by which to evaluate and improve collaborative care in primary care. This novel framework sets standards for clinical programs, and promotes data-driven quality improvement (QI) efforts. The framework has attracted interest in Canada and the United States.

Dr. Sunderji also uses her education leadership activities to promote knowledge translation of evidence-based models of collaborative care by supporting practicing healthcare providers and trainees to implement and improve guideline-based, measurement-based, population-based care in their clinical practice settings. Thus, the aforementioned quality framework and measures also identify higher order outcomes at the patient, population, and health system levels, that can be incorporated into educational program evaluation.


vigodDr. Simone Vigod is a Psychiatrist, Scientist and Lead of the Reproductive Life Stages Program at Women’s College Hospital in Toronto, Ontario. She is an Assistant Professor in the Department of Psychiatry at the University of Toronto (UofT), and an Adjunct Scientist at the Institute for Clinical Evaluative Sciences (ICES).  She obtained her medical degree from UofT (2003), and completed her residency in psychiatry in Toronto (2009).  Having obtained a masters degree in clinical epidemiology (2011), Dr. Vigod has built a successful research program focusing on epidemiology and treatment of women with mental health issues across the lifespan.


voineskosDr. Aristotle Voineskos is an Associate Professor in the Department of Psychiatry, Faculty of Medicine at the University of Toronto. He is the Director of the Slaight Family Centre for Youth in Transition, and Head of the Kimel Family Translational Imaging-Genetics Laboratory.  Dr. Voineskos holds a special interest in leading early identification and intervention for young people with emerging mental illness. A related area of Dr. Voineskos’s work includes using structural and functional neuroimaging in medication-based, brain stimulation, and behavioural treatment studies in schizophrenia and related disorders. This approach identifies the effects of existing and new treatments on brain structure and function, and aims to use neuroimaging to predict treatment response.